MicroRNAs: Clinical Relevance in Colorectal Cancer.
MicroRNAs: Clinical Relevance in Colorectal Cancer.
复制标题
DOI：
10.3390/ijms161226080
复制
发表时间：
2015-11-25
影响因子：
5.6
通讯作者：
Ling H
中科院分区：
文献类型：
--
作者：
Thomas J;Ohtsuka M;Pichler M;Ling H
结直肠癌是世界范围内最常见的癌症诊断和死亡原因之一。MicroRNA是一类小的非编码调节RNA，与结直肠癌有很强的相关性。通过靶信使RNA的抑制，microRNA调节许多细胞途径，如参与细胞增殖、凋亡和分化的途径。microRNA的利用在结直肠癌的诊断和预后中显示出显著的前景，由于其独特的表达谱与癌症类型和恶性肿瘤的相关性。此外，具有模拟物或拮抗剂的microRNA治疗剂在临床前研究中显示出巨大的前景，这鼓励了其在结直肠癌患者中的临床应用的进一步发展。microRNA影响多个下游通路的独特能力代表了癌症治疗的新方法。虽然仍处于发展早期，但我们相信microRNA可以在不久的将来用作结直肠癌的生物标志物和治疗靶点。
Colorectal cancer is one of the most common cancer diagnoses and causes of mortality worldwide. MicroRNAs are a class of small, non-coding regulatory RNAs that have shown strong associations with colorectal cancer. Through the repression of target messenger RNAs, microRNAs modulate many cellular pathways, such as those involved in cell proliferation, apoptosis, and differentiation. The utilization of microRNAs has shown significant promise in the diagnosis and prognosis of colorectal cancer, owing to their unique expression profile associations with cancer types and malignancies. Moreover, microRNA therapeutics with mimics or antagonists show great promise in preclinical studies, which encourages further development of their clinical use for colorectal cancer patients. The unique ability of microRNAs to affect multiple downstream pathways represents a novel approach for cancer therapy. Although still early in its development, we believe that microRNAs can be used in the near future as biomarkers and therapeutic targets for colorectal cancer.